In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses

Chang-Kyung KANG; Moon-Woo SEONG; Su-Jin CHOI; Taek-Soo KIM; Pyoeng-Gyun CHOE; Sang-Hoon SONG; Nam-Joong KIM; Wan-Beom PARK; Myoung-don OH.
The Korean Journal of Internal Medicine ; : 782-787, 2020.
Artículo | WPRIM | ID: wpr-831790

Documentos relacionados

  1. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
  2. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
  3. Advances in the Omicron variant development.
  4. Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
  5. In vitro activity of cysteamine against SARS-CoV-2 variants.
  6. Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.
  7. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
  8. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  9. Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures.
  10. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.